Asia-Pacific geriatric medicine market is projected to grow at a significant CAGR of 6.8% during the forecast period. Asia-Pacific has some of the economies with the rising healthcare infrastructure, such as India and China. Along with this, these economies are counted under one of the economies with a large population base. Therefore, the geriatric population is rising at a considerable rate. As per the UN, there were 703 million older persons aged 65 or over in 2019, globally. Eastern and South-Eastern Asia were home to the largest number of the world’s older population (260 million), followed by Europe and Northern America (over 200 million).
A full report of Asia-Pacific Geriatric Medicine Market is available at: https://www.omrglobal.com/industry-reports/asia-pacific-geriatric-medicine-market
Over the next three decades, the global number of older persons is projected to be more than double, reaching over 1.5 billion persons in 2050. All regions will see an increase in the size of their older population between 2019 and 2050. The largest increase (+312 million persons) is projected to occur in Eastern and South-Eastern Asia, growing from 261 million in 2019 to 573 million persons aged 65 years or over in 2050. These statistics show that the demand for the healthcare treatment of the elderly is increasing in these economies, which in turn, is offering growth opportunities to the Asia-Pacific geriatric medicine market.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/asia-pacific-geriatric-medicine-market
Market Coverage
- Study Period- 2019-2026
- Base year- 2019
- Forecast period- 2020-2026
- Segments Covered- By Therapeutics and By Condition
- Countries Covered- China, India, Japan, and Rest of Asia-Pacific
- Key Companies Profiled- Aurobindo Pharma, Ltd. Mankind Pharma, Cipla Ltd., Sun Pharmaceuticals Industries Ltd., Astellas Pharma Inc., and Teva Pharmaceuticals Industries Ltd.
Key questions addressed by the report
- What is the market growth rate during the forecast period?
- Which segment/region dominates the market in the base year?
- Which segment/region will project the fastest growth in the market during the forecast period?
- How COVID-19 will impact the market growth in 2020 and coming years?
o Recovery Timeline
o Deviation from the pre-COVID-19
o Most affected region/segment
o Recommendations
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Asia-Pacific Geriatric Medicine Market – Segmentation
By Therapeutics
- Analgesic
- Anticoagulant
- Antihypertensive
- Antidiabetic
- Others (Statins and Antipsychotic)
By Condition
- Cardiovascular Diseases (CVDs)
- Diabetes
- Neurological
- Cancer
- Respiratory
- Others (Arthritis and Osteoporosis)
This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.
